Alerje
Latest round
- Seed
Last raised
- Jul 2023
Total raised
- $2M
Investors
- 3
About Alerje
a. Alerje operates as a software firm with a focus on offering a platform with a range of remote therapeutic management (RTM) tools for food allergies to facilitate the administration of OIT regimens and ensure that patients and physicians successfully complete them. In September 2023, Alerje, Inc. Alerje offers an Oral Immunotherapy (OIT) management platform that simplifies the OIT process by keeping patients connected with their allergists, providing treatment-specific resources, tracking doses, and celebrating milestones. The company’s flagship product, the Omniject™ epinephrine auto-injector, attaches to a smartphone case for convenience, ensuring it is accessible and kept at an optimal temperature. The Omniject™ epinephrine auto-injector also provides automatic alerts to allergists, first responders, and a support network when activated.
Who invested in Alerje
3 investors across 2 rounds
See all investors in Alerje
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Alerje
Who invested in Alerje?
Alerje has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Alerje raised?
Alerje has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Alerje last raise money?
Alerje's most recent round on record is a Seed, in Jul 2023.
What does Alerje do?
Alerje is a software company.
Where is Alerje headquartered?
Alerje is headquartered in Detroit, US.
Which VCs invest in companies like Alerje?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back software companies at Alerje's stage. Their profiles are linked below.
VCs backing software startups at Seed
Raising like Alerje? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.